Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
RARE Ultragenyx Pharmaceutical	$33.16 -2.2%	$39.58	$29.59 ▼ $60.37	$3.11B	0.61	806,126 shs	1.77 million shs
RYTM Rhythm Pharmaceuticals	$57.83 -4.0%	$54.58	$35.17 ▼ $68.58	$3.66B	2.32	540,052 shs	907,135 shs
SWTX SpringWorks Therapeutics	$34.43 -7.2%	$48.67	$28.21 ▼ $62.00	$2.58B	0.79	1.36 million shs	2.25 million shs
XERS Xeris Biopharma	$3.95 -8.8%	$4.38	$1.69 ▼ $6.07	$608.06M	1.37	1.85 million shs	4.24 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
RARE Ultragenyx Pharmaceutical	-2.21%	-5.61%	-13.49%	-21.18%	-35.75%
RYTM Rhythm Pharmaceuticals	-3.98%	+16.08%	+15.52%	+2.96%	+40.71%
SWTX SpringWorks Therapeutics	-7.25%	-20.06%	-32.34%	-19.93%	-20.98%
XERS Xeris Biopharma	-8.78%	-19.06%	-10.02%	+16.18%	+99.49%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
RARE Ultragenyx Pharmaceutical	4.2948 of 5 stars	4.5	1.0	3.8	3.5	2.5	0.6
RYTM Rhythm Pharmaceuticals	4.3027 of 5 stars	4.5	3.0	4.3	2.6	0.8	0.6
SWTX SpringWorks Therapeutics	1.9744 of 5 stars	3.5	2.0	0.0	3.0	0.8	0.6
XERS Xeris Biopharma	4.2285 of 5 stars	4.4	1.0	4.2	3.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$92.79	179.81% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$74.92	29.56% Upside
SWTX SpringWorks Therapeutics	3.00	Buy	$73.20	112.61% Upside
XERS Xeris Biopharma	2.80	Moderate Buy	$6.10	54.43% Upside

Current Analyst Ratings Breakdown

Latest XERS, RARE, RYTM, and SWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $92.00
4/8/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $80.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $91.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$63.00 ➝ $63.00
3/27/2025	RARE Ultragenyx Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$104.00 ➝ $117.00
3/24/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
3/18/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$64.00 ➝ $66.00
3/17/2025	RARE Ultragenyx Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
3/7/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$72.00 ➝ $72.00
3/7/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00

(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
RARE Ultragenyx Pharmaceutical	$560.23M	5.56	N/A	N/A	$2.76 per share	12.01
RYTM Rhythm Pharmaceuticals	$130.13M	28.10	N/A	N/A	$2.87 per share	20.15
SWTX SpringWorks Therapeutics	$191.59M	13.47	N/A	N/A	$10.01 per share	3.44
XERS Xeris Biopharma	$203.07M	2.99	N/A	N/A	($0.05) per share	-79.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
RARE Ultragenyx Pharmaceutical	-$569.18M	-$6.34	N/A	N/A	N/A	-101.60%	-193.80%	-38.15%	5/1/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$184.68M	-$4.35	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	5/6/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$325.10M	-$3.48	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	5/1/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.38	N/A	N/A	N/A	-33.69%	N/A	-17.38%	5/8/2025 (Estimated)

Latest XERS, RARE, RYTM, and SWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	N/A	N/A	N/A	$57.61 million	N/A
5/6/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.67	N/A	N/A	N/A	$40.43 million	N/A
5/1/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.58	N/A	N/A	N/A	$145.98 million	N/A
5/1/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.79	N/A	N/A	N/A	$66.93 million	N/A
2/26/2025	Q4 2024	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.72	-$0.03	-$0.72	$38.48 million	$41.83 million
2/20/2025	Q4 2024	SWTX SpringWorks Therapeutics	-$0.66	-$1.04	-$0.38	-$1.04	$60.53 million	$61.55 million
2/13/2025	Q4 2024	RARE Ultragenyx Pharmaceutical	-$1.32	-$1.39	-$0.07	-$1.39	$163.23 million	$164.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
RARE Ultragenyx Pharmaceutical	N/A	2.37	2.65
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34
SWTX SpringWorks Therapeutics	N/A	6.16	6.02
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
RARE Ultragenyx Pharmaceutical	97.67%
RYTM Rhythm Pharmaceuticals	N/A
SWTX SpringWorks Therapeutics	N/A
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
RARE Ultragenyx Pharmaceutical	5.80%
RYTM Rhythm Pharmaceuticals	5.60%
SWTX SpringWorks Therapeutics	7.61%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
RARE Ultragenyx Pharmaceutical	1,310	93.89 million	86.99 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.22 million	58.02 million	Optionable
SWTX SpringWorks Therapeutics	230	74.94 million	68.73 million	Optionable
XERS Xeris Biopharma	290	153.94 million	142.28 million	Optionable

XERS, RARE, RYTM, and SWTX Headlines

Recent News About These Companies

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's Why

April 3, 2025 | marketbeat.com

AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 31, 2025 | marketbeat.com

Xeris Announces Changes to Its Board of Directors

March 28, 2025 | finance.yahoo.com

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?

March 25, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 23, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

March 22, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's Why

March 22, 2025 | marketbeat.com

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

March 20, 2025 | zacks.com

12 Best Stocks to Invest in for a Stock Market Game

March 20, 2025 | insidermonkey.com

Xeris enters a whole new market for one of its main pharma offerings

March 20, 2025 | chicagobusiness.com

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

March 19, 2025 | insidermonkey.com

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 18, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?

March 18, 2025 | marketbeat.com

FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid

March 17, 2025 | markets.businessinsider.com

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

March 17, 2025 | finance.yahoo.com

Globeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 17, 2025 | marketbeat.com

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

March 16, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Here's What Happened

March 15, 2025 | marketbeat.com

Xeris Biopharma Holdings Share Price (XERS.US)

March 12, 2025 | lse.co.uk

Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High - Should You Buy?

March 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
Everything About Amazon Stock Signals a Buy—Time to Load Up?
By Sam Quirke | March 20, 2025
View Everything About Amazon Stock Signals a Buy—Time to Load Up?
Samsara Stock Plunges, But Technicals Flash a Buy Signal
By Sam Quirke | March 12, 2025
View Samsara Stock Plunges, But Technicals Flash a Buy Signal

XERS, RARE, RYTM, and SWTX Company Descriptions

Ultragenyx Pharmaceutical NASDAQ:RARE

$33.16 -0.75 (-2.21%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$35.48 +2.32 (+7.00%)

As of 04:29 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$57.83 -2.40 (-3.98%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$57.84 +0.01 (+0.02%)

As of 06:13 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

SpringWorks Therapeutics NASDAQ:SWTX

$34.43 -2.69 (-7.25%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$35.70 +1.28 (+3.70%)

As of 05:48 AM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Xeris Biopharma NASDAQ:XERS

$3.95 -0.38 (-8.78%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$4.08 +0.13 (+3.16%)

As of 04/10/2025 07:52 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time